Welcome to our dedicated page for Immuneering SEC filings (Ticker: IMRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Immuneering Corporation’s (Nasdaq: IMRX) SEC filings, offering a detailed view of how the clinical-stage oncology company reports its operations, financings, and key developments. Immuneering’s Class A common stock is listed on The Nasdaq Global Market, and its Exchange Act reports and current reports on Form 8‑K document material events and corporate actions related to its Deep Cyclic Inhibitor programs.
Through Forms 10‑K and 10‑Q, investors can review Immuneering’s descriptions of its business, risk factors, research and development activities, and financial condition. Current reports on Form 8‑K capture specific events such as underwritten public offerings of Class A common stock, private placements with institutional investors, entry into material definitive agreements, and announcements of clinical data from the atebimetinib program. For example, recent 8‑K filings describe the company’s securities purchase agreement with a Sanofi subsidiary, the terms of a public offering, and updated interim data from a Phase 2a trial of atebimetinib plus modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer.
On Stock Titan, these filings are updated in near real time as they appear on EDGAR and are paired with AI-powered summaries that highlight the most important points. Long, technical documents are distilled to explain how financings affect Immuneering’s cash runway, what new clinical or regulatory milestones are disclosed, and how agreements such as equity distribution arrangements or clinical collaborations fit into the company’s strategy. Users can also track sections that discuss patent protection for atebimetinib, including the U.S. composition of matter patent, and references to planned pivotal Phase 3 trials and combination studies in non-small cell lung cancer.
In addition, this page allows investors to quickly locate any insider transaction reports on Form 4, proxy statements on Schedule 14A, and registration statements or prospectus supplements related to securities offerings, when available. By combining structured access to Immuneering’s filings with AI explanations, the platform helps readers understand how regulatory disclosures relate to the company’s Deep Cyclic Inhibitor pipeline, clinical development plans, and capital structure without having to parse every page manually.
Form 4 discloses that Benjamin J. Zeskind – President, CEO, Director and 10% owner of Immuneering Corp. (IMRX) – purchased additional Class A common shares on two consecutive days.
- 07/01/2025: 2,985 shares acquired at a weighted-average price of $3.3792.
- 07/02/2025: 7,015 shares acquired at a weighted-average price of $3.5342.
Following these open-market purchases (Transaction Code P), Zeskind now owns 2,305,837 shares directly and 894,927 shares indirectly through the Benjamin J. Zeskind 2020 Family Trust (sole trustee: Lisa Schwartz).
The filing signals incremental insider confidence, although the 10,000-share purchase represents less than 0.5% of Zeskind’s combined direct and indirect holdings. No derivative transactions were reported, and no sales occurred.
Immuneering Corp. (IMRX) Form 4 filing: On 24 June 2025 the company reported two open-market insider purchases by Chief Scientific Officer Brett Matthew Hall.
• 20 Jun 2025 – Hall bought 7,415 Class A common shares at a weighted-average price of $2.6999.
• 23 Jun 2025 – Hall bought 6,007 Class A common shares at a weighted-average price of $2.4299, with individual trades executed between $2.4101 and $2.4299 (per footnote 1). Both transactions were coded “P,” confirming they were purchases rather than option exercises.
No derivative securities were reported in Table II. Following the purchases Hall now directly owns 359,318 Class A shares, up from 345,896 beforehand—an increase of roughly 3.9 %. The filing does not mark the Rule 10b5-1 safe-harbor box and contains no amendments or dispositions.
Immuneering Corporation (IMRX) filed a Form 4 on 24-Jun-2025 disclosing a small insider purchase. Chief Business Officer Harold E. Brakewood acquired 1,900 shares of Class A common stock on 20-Jun-2025 at an average price of $2.5285 per share, for an estimated total cost of about $4,805. Following the transaction, Brakewood’s direct beneficial ownership rose from 3,900 to 5,800 shares.
The filing reports no derivative activity and contains no other transactions or amendments. Because the share count and dollar value are modest relative to Immuneering’s public float, the transaction is considered routine and unlikely to materially affect the company’s capital structure or near-term valuation. Nevertheless, insider purchases can signal management’s confidence in the company’s prospects, which some investors view positively.
Form 4 filing overview for Immuneering Corp (IMRX): Director Peter Feinberg reported an open-market purchase of 25,000 Class A common shares on 06/18/2025 at a weighted-average price of $2.5275. The transaction was executed through multiple trades between $2.07 and $2.96.
Post-transaction ownership: Feinberg now holds 136,766 shares directly. In addition, he retains indirect ownership as general partner of three entities: 392,242 shares via PF Associates L.P., 476,615 shares via PEF LLC, and 115,441 shares via S4K Investments LLC, bringing his total reported beneficial ownership to approximately 1.12 million IMRX shares.
Key takeaways for investors:
- The filing reflects a net increase in insider holdings; no dispositions were reported.
- The purchase price is near recent trading lows, signalling potential confidence by a board member in the company’s valuation.
- No 10b5-1 plan was checked, indicating the transaction was not pre-scheduled under Rule 10b5-1.
Immuneering Corporation (Nasdaq: IMRX) filed a Rule 424(b)(5) prospectus supplement dated June 23, 2025 that updates its existing at-the-market (ATM) offering program.
Key points:
- Public float: Updated to approximately $83.1 million, calculated on 30,016,759 non-affiliate shares at $2.77 on 6/18/25.
- Because float now exceeds $75 million, IMRX is no longer subject to the sales limitation of Form S-3 General Instruction I.B.6, which had capped sales to one-third of public float over any 12-month period.
- ATM activity to-date: 6,155,556 shares sold for gross proceeds of $18.7 million.
- Remaining capacity: Company may now issue up to an additional $31.29 million of Class A common stock through Piper Sandler under the 8/10/22 Equity Distribution Agreement.
- Market context: Last reported share price on 6/20/25 was $2.56, implying potential dilution if new shares are issued near current levels.
Investors should review the “Risk Factors” section referenced in the base ATM prospectus, as the filing states that investing in IMRX shares involves a high degree of risk.
Immuneering Corporation (IMRX) – Form 4 insider transaction: On 06/18/2025, President, CEO, Director and 10% owner Benjamin J. Zeskind bought 21,000 shares of Class A common stock on the open market at a weighted-average price of $2.3878 per share (trades ranged $2.31-$2.44). The filing was signed on 06/20/2025.
Following the purchase, Zeskind directly owns 2,302,852 shares. In addition, an indirect holding of 894,927 shares is held by the Benjamin J. Zeskind 2020 Family Trust, for which his spouse serves as sole trustee. The transaction was coded “P” (open-market purchase), indicating an increase in ownership. The form does not reference any Rule 10b5-1 trading plan.
The purchase represents roughly 0.9% of Zeskind’s direct stake and signals continued insider support, but the absolute amount (≈$50 k) is modest relative to his existing 3.2 million-share economic interest.
FAQ
What is the current stock price of Immuneering (IMRX)?
What is the market cap of Immuneering (IMRX)?
